Current Medical Diagnosis &Treatment 2025
Editors: Likely Maxine A. Papadakis, Stephen J. McPhee, and Michael W. Rabo
Publisher: McGraw Hill (typically released in September 2024 for the 2025 edition).
Audience: Clinicians, residents, medical students, and NPs/PAs seeking concise, evidence-based guidance for adult inpatient and outpatient care.
Expected Features (Based on Prior Editions):
Updated Guidelines:
Revised recommendations from major organizations (e.g., ADA, ACC/AHA, IDSA, CDC) on diabetes, cardiovascular disease, infectious diseases, and cancer screening.
COVID-19 management updates, including long COVID and vaccination strategies.
New and Expanded Content:
Emerging topics: GLP-1 agonists (e.g., semaglutide, tirzepatide) for obesity and diabetes, CRISPR-based therapies, and advances in immunotherapy for cancer.
Expanded mental health coverage: Psychedelics (e.g., psilocybin) for depression, updated DSM-6 (if released) criteria.
Health equity: Bias mitigation in diagnostics/treatment.
Drug Updates:
FDA-approved drugs in 2023–2024 (e.g., new antibiotics, Alzheimer’s therapies like lecanemab).
Drug safety alerts (e.g., Ozempic/Wegovy side effects, drug shortages).
Digital Tools:
Access to AccessMedicine platform for eBook, algorithms, and self-assessment quizzes.
Integration of AI in diagnostics (e.g., AI-assisted imaging interpretation).
Format:
Quick-reference tables for differential diagnoses, drug dosages, and lab values.
Evidence ratings (e.g., strength of recommendations, clinical trial data).
Potential New Chapters/Topics (Speculative):
Long COVID: Multidisciplinary management strategies.
Climate Change and Health: Heat-related illnesses, vector-borne diseases.
Telemedicine: Best practices post-pandemic.
Gene Therapy: Applications in sickle cell disease, hemophilia